We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $253M
Founded date: 2019
Investors 6
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 20.03.2024 | F-Prime Ca... | fprimecapi... |
| 23.03.2024 | Forbion | forbion.co... |
| 21.03.2024 | Ysios Capi... | ysioscapit... |
| 13.04.2024 | Red Tree V... | redtreevc.... |
| 21.03.2024 | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.03.2024 | Series B | $157M | F-Prime Ca... |
| 04.08.2021 | Series A | $64M | - |
| 25.06.2020 | Series A | $32M | - |
Mentions in press and media 18
| Date | Title | Description |
| 21.03.2024 | Engrail Therapeutics Secures USD 157 Mn in Series B from F-Prime Capital and Others With the raised funding, the neuroscience firm aims to propel the advancement of the company's pipeline through mult... | - |
| 20.03.2024 | Engrail Therapeutics Secures $157M in Series B Funding | Engrail Therapeutics, a precision neuroscience company based in San Diego, CA, has closed a $157M Series B financing round. The funding, led by F-Prime Capital, Forbion, and Norwest Venture Partners, will fuel the advancement of Engrail's p... |
| 20.03.2024 | Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies | Proceeds to Support Advancement of Engrail's Pipeline for Neuropsychiatric and Neurodevelopmental Disorders SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on... |
| 19.03.2024 | Engrail Therapeutics raises $157M Series B | Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round. Th... |
| 19.03.2024 | Engrail Therapeutics raises $157 million in funding from F-Prime Capital, others | - |
| 19.03.2024 | Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies | - |
| 19.03.2024 | Engrail Therapeutics raises $157 million in funding from F-Prime Capital, others | Vikram Sudarsan, president and CEO of Engrail Therapeutics Engrail Therapeutics, a clinical stage company developing therapies against central nervous system (CNS) disorders on Tuesday said it has raised $157 million in Series B financing r... |
| 19.03.2024 | Engrail Therapeutics Closes $157M Series B Financing Round | Engrail Therapeutics, a San Diego, CA-based precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, raised $157M in Series B funding. The round was led by F-Prime Capital, Fo... |
| 19.03.2024 | Forbion co-leads oversubscribed $157M Series B Financing Round in Engrail Therapeutics | • Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorders • Investment marks the ninth from Forbion’s Growth Opportunities II Fund Naarden, The Netherlands – March 19, 2024 – Forbion, a le... |
| 19.03.2024 | Engrail closes $157M series B, fueled by investors’ renewed interest in neuropsychiatry | - |
Show more